

MMP-13 inhibitors

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3 DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	4 JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	5 JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	6 JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	7 JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	8 JAN 30	Saved answer limit increased
NEWS	9 FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	10 FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	11 FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	12 FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	13 FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	14 FEB 28	TOXCENTER reloaded with enhancements
NEWS	15 FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	16 MAR 01	INSPEC reloaded and enhanced
NEWS	17 MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	18 MAR 08	X.25 communication option no longer available after June 2006
NEWS	19 MAR 22	EMBASE is now updated on a daily basis
NEWS	20 APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	21 APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	22 APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	23 APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	24 APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	25 APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS EXPRESS	FEBRUARY 15	CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS	STN Operating Hours Plus Help Desk Availability	
NEWS LOGIN	Welcome Banner and News Items	
NEWS IPC8	For general information regarding STN implementation of IPC 8	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

MMP-13 inhibitors

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:35:14 ON 21 APR 2006

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:35:21 ON 21 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 APR 2006 HIGHEST RN 881169-11-5

DICTIONARY FILE UPDATES: 19 APR 2006 HIGHEST RN 881169-11-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s guanosine/cn

L1 1 GUANOSINE/CN

=> s beta-carotene/cn

L2 0 BETA-CAROTENE/CN

=> s retinoic(w)acid/cn

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

FIELD CODE - 'AND' OPERATOR ASSUMED 'RETINOIC(W)ACID/CN'

2053 RETINOIC

0 ACID/CN

L3 0 RETINOIC(W)ACID/CN

MMP-13 inhibitors

=> s (retinoic(w)acid)/cn
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'RETINOIC(W)ACID'
0 RETINOIC/CN
0 ACID/CN
L4 0 (RETINOIC(W)ACID)/CN

=> s retinoic/cn
L5 0 RETINOIC/CN

=> s (zinc acetate)/cn
L6 1 (ZINC ACETATE)/CN

=> s (retinoic acid)/cn
L7 1 (RETINOIC ACID)/CN

=> s (beta carotene)/cn
L8 0 (BETA CAROTENE)/CN

=> s (guano?)/cn
L9 35274 (GUANO?)/CN

=> sel L1
E1 THROUGH E13 ASSIGNED

=> sel L6
E14 THROUGH E21 ASSIGNED

=> Sel L7
E22 THROUGH E59 ASSIGNED

=> file medline caplus biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	55.55	55.76

FILE 'MEDLINE' ENTERED AT 11:38:05 ON 21 APR 2006

FILE 'CAPLUS' ENTERED AT 11:38:05 ON 21 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 11:38:05 ON 21 APR 2006
Copyright (c) 2006 The Thomson Corporation

=> s (organ or tissue)(w)regeneration
L10 0 (ORGAN OR TISSUE)(W) REGENERATION

=> s (organ or tissue)(w)regeneration
L11 8077 (ORGAN OR TISSUE)(W) REGENERATION

=> s L11 and E1-E59
2 FILES SEARCHED...

L12 20 L11 AND ("B-D-RIBOFURANOSIDE, GUANINE-9"/BI OR "GUANINE
RIBONUCLEOSIDE"/BI OR "GUANINE, 9-B-D-RIBOFURANOSYL-"/BI
OR GUANOSINE/BI OR "INOSINE, 2-AMINO-"/BI OR "NSC 19994"/BI OR
VERNINE/BI OR 118-00-3/BI OR "2-AMINO-1,9-DIHYDRO-9-B-D-RIBO
FURANOSYL-6H-PURIN-6-ONE"/BI OR 484-80-0/BI OR "6H-PURIN-6-ONE,
2-AMINO-1,9-DIHYDRO-9-B-D-RIBOFURANOSYL-"/BI OR 685891-87-6/
BI OR 85-30-3/BI OR GALZIN/BI OR "SILTEX CL 4"/BI OR "ZINC ACETAT
E"/BI OR "ZINC DIACETATE"/BI OR "ZINC(II) ACETATE"/BI OR 128514-8

MMP-13 inhibitors

3-0/BI OR 131853-00-4/BI OR 557-34-6/BI OR "B-RETINOIC ACID"
/BI OR "(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)
-2,4,6,8-NONATETRAENOIC ACID"/BI OR ABEREL/BI OR "AGN 100335"/BI
OR AIROL/BI OR AKNOTEN/BI OR "ALL-(E)-RETINOIC ACID"/BI OR "ALL-
TRANS-B-RETINOIC ACID"/BI OR "ALL-TRANS-RETINOIC ACID"/BI
OR ALL-TRANS-TRETINOIN/BI OR "ALL-TRANS-VITAMIN A ACID"/BI OR
ATRA/BI OR ATRAGEN/BI OR "CORDES VAS"/BI OR DERMAIROL/BI OR EPI-A
BEREL/BI OR EUDYNA/BI OR "NSC

=> s L12 and py<2000

1 FILES SEARCHED...

L13 5 L12 AND PY<2000

=> dup rem L13

PROCESSING COMPLETED FOR L13

L14 5 DUP REM L13 (0 DUPLICATES REMOVED)

=> d L14 1-5 ti abs bib

L14 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Cloning, sequence, and therapeutic use of DNA encoding human

retinoic acid receptor epsilon isoform

AB A human **retinoic acid** receptor epsilon (RAR ϵ)

polynucleotide and DNA (RNA) encoding such polypeptides are disclosed.

Also provided is a procedure for producing such polypeptide by recombinant techniques and utilizing such polypeptide for therapeutic purposes, for example, **tissue regeneration** and stimulation of the

immune and hematopoietic system. Methods of identifying ligands which stimulate the RAR ϵ are also claimed. Also disclosed are

diagnostic methods for detecting a mutation in the RAR ϵ receptor

coding sequence and detecting a level of the soluble form of the receptors in a sample derived from a host.

AN 1999:100797 CAPLUS

DN 130:164016

TI Cloning, sequence, and therapeutic use of DNA encoding human

retinoic acid receptor epsilon isoform

IN Cao, Liang; Ni, Jian; Fleischmann, Robert D.

PA Human Genome Sciences, Inc., USA

SO U.S., 22 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5869284	A	19990209	US 1995-466120	19950606 <--
	JP 2002034583	A2	20020205	JP 2001-189781	19940624
	US 2003129701	A1	20030710	US 2002-278945	20021024
PRAI	JP 1996-503085	A3	19940624		
	WO 1994-US7266	A1	19940624		
	US 1995-466120	A3	19950606		
	US 1998-22789	B1	19980212		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Expression of regeneration-associated cytoskeletal proteins reveals

differences and similarities between regenerating organs

AB The unique events which allow regeneration of an entire organ to occur are formation of a specialized wound epidermis and accumulation of progenitor cells (blastemal cells) at the amputated surface to form a blastema. In order to identify some of the mol. events underlying the early stages of the regenerative process which are either common to different systems or

MMP-13 inhibitors

specific to one of them, we have investigated whether mols. which are induced in limb blastemas are also expressed in skin repair and during regeneration of other complex body structures (lower jaws, upper jaws, and tails). In addition, we have addressed the issue of the identity of progenitor cells during jaw development and regeneration by analyzing the expression of limb blastemal markers in the developing head and face. We have focused on cytoskeletal components, and particularly on the epidermal keratin NvKII, the simple epithelial keratins 8 and 18 and 22/18, because they are among the few mols. which have been shown to be associated with regeneration in the limb and may play significant roles in various developmental processes. Some important findings emerge from this study: 1) Expression of the epidermal keratin NvKII, unlike that of its mammalian homolog K6, is not simply induced in response to wounding, but is associated with regeneration of specific organs. In fact, NvKII is expressed in regenerating limbs and tails, but not in upper or in lower jaw regenerates, demonstrating the existence of mol. differences in the composition of the wound epidermis in these systems. This, together with the fact that NvKII mRNA is regulated by **retinoic acid**, which differentially affects patterning of limbs and jaws, argues for distinct inductive abilities of the wound epidermis in different organs. 2) In contrast to the differential expression of the epidermal keratin NvKII, the regeneration-associated cytoskeletal mols. identified in limb blastemal cells are expressed in a similar fashion in jaw and tail blastemas. Therefore, it appears that similar cellular events lead to the establishment of an actively proliferating population of progenitor cells from the stump of different organs. Finally, the mesenchyme of the facial rudiments, unlike that of developing limb buds, expresses simple epithelial keratins. Thus, it appears that mesenchymal progenitor cells of developing and regenerating jaws are alike in regard to their intermediate filament content, and this may be related to nerve-dependent growth control of progenitor cells in different developing and regenerating systems.

AN 1997:768186 CAPLUS

DN 128:59892

TI Expression of regeneration-associated cytoskeletal proteins reveals differences and similarities between regenerating organs

AU Ferretti, Patrizia; Ghosh, Sukla

CS Developmental Biology Unit, Institute of Child Health UCL, London, WC1N 1EH, UK

SO Developmental Dynamics (1997), 210(3), 288-304

CODEN: DEDYEI; ISSN: 1058-8388

PB Wiley-Liss, Inc.

DT Journal

LA English

RE.CNT 89 THERE ARE 89 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI human **retinoic acid** receptor epsilon cloning and expression and purification in baculovirus system and therapeutic use

AB Human (RAR ϵ) **retinoic acid** receptor was cloned and expressed and purified in baculovirus. Tissue-specific expression of RAR ϵ is presented. Utilization of RAR ϵ for therapeutic purposes including **tissue regeneration** and stimulation of the immune and hematopoietic system is discussed. Also disclosed are methods of identifying ligands which stimulate the RAR ϵ .

AN 1996:134170 CAPLUS

DN 124:167524

TI human **retinoic acid** receptor epsilon cloning and expression and purification in baculovirus system and therapeutic use

IN Cao, Liang; Ni, Jian; Fleischmann, Robert D.

PA Human Genome Sciences, Inc., USA

SO PCT Int. Appl., 42 pp.

MMP-13 inhibitors

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9600242	A1	19960104	WO 1994-US7266	19940624 <--
	W: AU, CA, CN, JP, KR, NZ, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9474712	A1	19960119	AU 1994-74712	19940624 <--
	EP 769023	A1	19970423	EP 1994-924450	19940624 <--
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	JP 10501986	T2	19980224	JP 1996-503085	19940624 <--
	JP 2002034583	A2	20020205	JP 2001-189781	19940624
	US 2003129701	A1	20030710	US 2002-278945	20021024
PRAI	JP 1996-503085	A3	19940624		
	WO 1994-US7266	W	19940624		
	US 1995-466120	A3	19950606		
	US 1998-22789	B1	19980212		

L14 ANSWER 4 OF 5 MEDLINE on STN

TI EGF receptor activities in mammalian development.

AB The receptor for epidermal growth factor (EGF) and its analog transforming growth factor alpha (TGF alpha) is ubiquitous, implying quite general roles for EGF/TGF alpha in cell viability and tissue maintenance in adult tissues. There is also evidence that the EGF receptor is active in promoting wound healing and **tissue regeneration** in adult organs, such as skin, liver, and intestinal epithelium. It is likely that EGF receptors have more specific roles during the gestation period. For example, we have detected EGF receptors on the 3.5-day blastocyst (trophectoderm) surface and since TGF alpha-like mRNA sequences and peptides have been detected at this time (Rappolee et al., Science 241:1823, 1988), there is a strong implication for autocrine stimulation in pre- and peri-implantation stage embryos. Paracrine stimulation between the embryo and maternal tissues is also likely since both receptors and TGF alpha are present in decidual cells. Therefore EGF receptors may take part in growth regulation of the early embryo and in the process of implantation. Other examples where EGF receptors may play specific roles during embryonic development are discussed.

AN 91104022 MEDLINE

DN PubMed ID: 2271181

TI EGF receptor activities in mammalian development.

AU Adamson E D

CS La Jolla Cancer Research Foundation, California.

NC CA 28427 (NCI)

HD21957 (NICHD)

SO Molecular reproduction and development, (1990 Sep) Vol. 27, No. 1, pp. 16-22.

Journal code: 8903333. ISSN: 1040-452X.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199102

ED Entered STN: 19910329

Last Updated on STN: 20000303

Entered Medline: 19910225

L14 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Effect of some products of tissue autolysis on the processes of degeneration

AB cf. ibid. 24, 487 (1952); C.A. 47, 12637i, 12638a; 50, 9551i. In the process of autolysis the following substances are formed: adenosine,

MMP-13 inhibitors

guanosine, adenine, guanine, hypoxanthine, xanthine, uric acid, adenosinetriphosphoric acid (ATP) and adenylic acid. To varying degrees these substances accelerate the proliferation of yeast cells, especially ATP, xanthine, and uric acid. In healing exptl. wounds in the rabbit ATP, adenylic acid, guanosine, adenine, and guanine augment the epithelization of the wounds. The addition of adenine, guanine, hypoxanthine, and ATP to the homogenates of granular tissue in all cases increases the power of granulation to reduce methylene blue. A study was made of the effect of ATP, adenylic acid, hypoxanthine, adenine, guanine, xanthine, and uric acid on the oxidation-reduction processes of the regenerating tissues. ATP, adenylic acid, and hypoxanthine raise the dehydrogenase activity of the liver; xanthine and uric acid lower the rate of methylene blue reduction by the liver tissue. This may be due to the fact that such substances in themselves can act as H acceptors. The addition of ATP, adenylic acid, adenosine, adenine, guanine, hypoxanthine, xanthine, and of uric acid raises the capacity for O absorption of the normal and regenerating liver tissue. The greater part of the substances studied, containing purine derivs. or purine bases, stimulate the growth of yeast cells and of regenerating tissue and also increase the rate of oxidation-reduction processes during **tissue regeneration**. This is due to the fact that purine-containing substances and purine bases can be utilized for the synthesis of nucleic acid and, as sources of coenzyme formation, can stimulate tissue cell metabolism and thereby tissue growth.

AN 1957:35551 CAPLUS

DN 51:35551

OREF 51:6803a-e

TI Effect of some products of tissue autolysis on the processes of degeneration

AU Palladina, L. I.; Gudina, A. M.

CS Inst. Biochem., Acad. Sci. Ukr. S.S.R., Kiev

SO Ukrain'skii Biokhimichnii Zhurnal (1946-1977) (1956), 28, 442-8; Russian summary, 449-50
CODEN: UBZHAZ; ISSN: 0372-3909

DT Journal

LA Unavailable

=> s wound(w)healing

L15 91158 WOUND(W) HEALING

=> s L15 and E1-E59

2 FILES SEARCHED...

L16 429 L15 AND ("B-D-RIBOFURANOSIDE, GUANINE-9"/BI OR "GUANINE RIBONUCLEOSIDE"/BI OR "GUANINE, 9-B-D-RIBOFURANOSYL-"/BI OR GUANOSINE/BI OR "INOSINE, 2-AMINO-"/BI OR "NSC 19994"/BI OR VERNINE/BI OR 118-00-3/BI OR "2-AMINO-1,9-DIHYDRO-9-B-D-RIBO FURANOSYL-6H-PURIN-6-ONE"/BI OR 484-80-0/BI OR "6H-PURIN-6-ONE, 2-AMINO-1,9-DIHYDRO-9-B-D-RIBOFURANOSYL-"/BI OR 685891-87-6/BI OR 85-30-3/BI OR GALZIN/BI OR "SILTEX CL 4"/BI OR "ZINC ACETAT E"/BI OR "ZINC DIACETATE"/BI OR "ZINC(II) ACETATE"/BI OR 128514-6 3-0/BI OR 131853-00-4/BI OR 557-34-6/BI OR "B-RETINOIC ACID" /BI OR "(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAENOIC ACID"/BI OR ABEREL/BI OR "AGN 100335"/BI OR AIROL/BI OR AKNOTEN/BI OR "ALL-(E)-RETINOIC ACID"/BI OR "ALL- TRANS-B-RETINOIC ACID"/BI OR "ALL-TRANS-RETINOIC ACID"/BI OR ALL-TRANS-TRETINOIN/BI OR "ALL-TRANS-VITAMIN A ACID"/BI OR ATRA/BI OR ATRAGEN/BI OR "CORDES VAS"/BI OR DERMAIROL/BI OR EPI-A BEREL/BI OR EUDYNA/BI OR "NSC

=> dup rem L16

PROCESSING COMPLETED FOR L16

L17 320 DUP REM L16 (109 DUPLICATES REMOVED)

MMP-13 inhibitors

=> s L17 and py<2000

1 FILES SEARCHED...

L18 179 L17 AND PY<2000

=> d L18 1-40 ti

L18 ANSWER 1 OF 179 MEDLINE on STN

TI **Retinoic acid** and CO2 laser resurfacing.

L18 ANSWER 2 OF 179 MEDLINE on STN

TI Bioactivities of nerve growth factor from Chinese cobra venom.

L18 ANSWER 3 OF 179 MEDLINE on STN

TI **Retinoic acid** and 1,25-dihydroxyvitamin D3 inhibit tenascin-C expression in rat glioma C6 cells.

L18 ANSWER 4 OF 179 MEDLINE on STN

TI Preoperative and postoperative topical **tretinoin** on high-tension excisional wounds and full-thickness skin grafts in a porcine model: A pilot study.

L18 ANSWER 5 OF 179 MEDLINE on STN

TI Expression of cartilage-derived **retinoic acid**-sensitive protein during healing of the rat tooth-extraction socket.

L18 ANSWER 6 OF 179 MEDLINE on STN

TI Synergistic inhibition of lysophosphatidic acid signaling by charged and uncharged local anesthetics.

L18 ANSWER 7 OF 179 MEDLINE on STN

TI Expression of midkine in normal and burn sites of rat skin.

L18 ANSWER 8 OF 179 MEDLINE on STN

TI Identification of heparin-binding EGF-like growth factor as a target in intercellular regulation of epidermal basal cell growth by suprabasal **retinoic acid** receptors.

L18 ANSWER 9 OF 179 MEDLINE on STN

TI Retinoid regulation of heparin-binding EGF-like growth factor gene expression in human keratinocytes and skin.

L18 ANSWER 10 OF 179 MEDLINE on STN

TI The healing effect of **all-trans retinoic acid** on epithelial corneal abrasions in rabbits.

L18 ANSWER 11 OF 179 MEDLINE on STN

TI The role of retinoids in **wound healing**.

L18 ANSWER 12 OF 179 MEDLINE on STN

TI Use of **tretinoin** in female health practice.

L18 ANSWER 13 OF 179 MEDLINE on STN

TI **Retinoic acid** regulation of renal tubular epithelial and vascular smooth muscle cell function.

L18 ANSWER 14 OF 179 MEDLINE on STN

TI Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change.

L18 ANSWER 15 OF 179 MEDLINE on STN

TI Care before and after laser skin resurfacing. A survey and review of the literature.

MMP-13 inhibitors

- L18 ANSWER 16 OF 179 MEDLINE on STN
TI Cellular retinol-binding protein-1 is transiently expressed in granulation tissue fibroblasts and differentially expressed in fibroblasts cultured from different organs.
- L18 ANSWER 17 OF 179 MEDLINE on STN
TI Expression of regeneration-associated cytoskeletal proteins reveals differences and similarities between regenerating organs.
- L18 ANSWER 18 OF 179 MEDLINE on STN
TI Altered wound arginine metabolism by corticosterone and **retinoic acid**.
- L18 ANSWER 19 OF 179 MEDLINE on STN
TI Ultrapulse carbon dioxide laser with CPG scanner for full-face resurfacing for rhytids, photoaging, and acne scars.
- L18 ANSWER 20 OF 179 MEDLINE on STN
TI A critical appraisal of high-energy pulsed carbon dioxide laser facial resurfacing for acne scars.
- L18 ANSWER 21 OF 179 MEDLINE on STN
TI Effects of **tretinoin** pretreatment on TCA chemical peel in guinea pig skin.
- L18 ANSWER 22 OF 179 MEDLINE on STN
TI **Wound healing** in elderly human skin.
- L18 ANSWER 23 OF 179 MEDLINE on STN
TI Effect of **retinoic acid** on **wound healing** of laser burns to porcine retinal pigment epithelium.
- L18 ANSWER 24 OF 179 MEDLINE on STN
TI Differential gene expression in migrating renal epithelial cells after wounding.
- L18 ANSWER 25 OF 179 MEDLINE on STN
TI Elements controlling the expression and induction of the skin hyperproliferation-associated keratin K6.
- L18 ANSWER 26 OF 179 MEDLINE on STN
TI Histologic study of dermabrasion and chemical peel in an animal model after pretreatment with **Retin-A**.
- L18 ANSWER 27 OF 179 MEDLINE on STN
TI Pretreatment of photoaged forearm skin with topical **tretinoin** accelerates healing of full-thickness wounds.
- L18 ANSWER 28 OF 179 MEDLINE on STN
TI Influence of digits, ectoderm, and **retinoic acid** on chondrogenesis by mouse interdigital mesoderm in culture.
- L18 ANSWER 29 OF 179 MEDLINE on STN
TI Effects of **tretinoin** tocoferil on gene expression of the extracellular matrix components in human dermal fibroblasts in vitro.
- L18 ANSWER 30 OF 179 MEDLINE on STN
TI CO₂, argon, and pulsed dye laser treatment of angiofibromas.
- L18 ANSWER 31 OF 179 MEDLINE on STN
TI Demonstration of 72-kDa and 92-kDa forms of type IV collagenase in human skin: variable expression in various blistering diseases, induction during

MMP-13 inhibitors

re-epithelialization, and decrease by topical glucocorticoids.

- L18 ANSWER 32 OF 179 MEDLINE on STN
TI Epidermis reconstructed from the outer root sheath of human hair follicle.
Effect of **retinoic acid**.
- L18 ANSWER 33 OF 179 MEDLINE on STN
TI Effect of protein kinase C inhibitors and activators on corneal
re-epithelialization in the rat.
- L18 ANSWER 34 OF 179 MEDLINE on STN
TI Histological analysis of forelimb regeneration in the California newt
Taricha granulosa.
- L18 ANSWER 35 OF 179 MEDLINE on STN
TI Effects of retinoids on endothelial cell proliferation, prostacyclin
production and platelet aggregation.
- L18 ANSWER 36 OF 179 MEDLINE on STN
TI The role of morphogens in endochondral ossification.
- L18 ANSWER 37 OF 179 MEDLINE on STN
TI Growth factors and corneal endothelial cells: II. Characterization of
epidermal growth factor receptor from bovine corneal endothelial cells.
- L18 ANSWER 38 OF 179 MEDLINE on STN
TI Topical **tretinoin** decreases healing times of
electroepilation-induced wounds.
- L18 ANSWER 39 OF 179 MEDLINE on STN
TI Methods to speed healing after skin biopsy or trichloroacetic acid
chemical peel.
- L18 ANSWER 40 OF 179 MEDLINE on STN
TI The prevention and management of postdermabrasion complications.

=> d L18 41-80 ti

- L18 ANSWER 41 OF 179 MEDLINE on STN
TI **Tretinoin** accelerates healing after trichloroacetic acid
chemical peel.
- L18 ANSWER 42 OF 179 MEDLINE on STN
TI TGF-beta and **retinoic acid**: regulators of growth and
modifiers of differentiation in human epidermal cells.
- L18 ANSWER 43 OF 179 MEDLINE on STN
TI EGF receptor activities in mammalian development.
- L18 ANSWER 44 OF 179 MEDLINE on STN
TI [Monoclonal antibodies and corneal cicatrization in rabbits].
Anticorps monoclonaux et cicatrisation corneenne chez le lapin.
- L18 ANSWER 45 OF 179 MEDLINE on STN
TI Granulation tissue that developed after a minor trauma in a psoriatic
patient on long-term etretinate therapy.
- L18 ANSWER 46 OF 179 MEDLINE on STN
TI Retinoids and butyrate modulate fibroblast growth and contraction of
collagen matrices.
- L18 ANSWER 47 OF 179 MEDLINE on STN

MMP-13 inhibitors

- TI Retinoid-induced potentiation of epidermal growth factor mitogenic effect on corneal endothelial cells.
- L18 ANSWER 48 OF 179 MEDLINE on STN
TI The role of topical agents in the healing of full-thickness wounds.
- L18 ANSWER 49 OF 179 MEDLINE on STN
TI The effect of retinoids on the migration of Tenon's capsule fibroblasts.
- L18 ANSWER 50 OF 179 MEDLINE on STN
TI The use of **retinoic acid** to probe the relation between hyperproliferation-associated keratins and cell proliferation in normal and malignant epidermal cells.
- L18 ANSWER 51 OF 179 MEDLINE on STN
TI Topical **tretinoin** and epithelial **wound healing**.
- L18 ANSWER 52 OF 179 MEDLINE on STN
TI Delayed **wound healing** and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment.
- L18 ANSWER 53 OF 179 MEDLINE on STN
TI Effects of polyprenoic acid on thermal injury.
- L18 ANSWER 54 OF 179 MEDLINE on STN
TI Topical **tretinoin**: indications, safety, and effectiveness.
- L18 ANSWER 55 OF 179 MEDLINE on STN
TI Treatment of corneal xerophthalmia in rabbits with micromolar doses of topical **retinoic acid**.
- L18 ANSWER 56 OF 179 MEDLINE on STN
TI The effect of 13-cis-**retinoic acid** on **wound healing** in dogs.
- L18 ANSWER 57 OF 179 MEDLINE on STN
TI **Tretinoin** in the preoperative and postoperative management of dermabrasion.
- L18 ANSWER 58 OF 179 MEDLINE on STN
TI Vitamin A and **wound healing**.
- L18 ANSWER 59 OF 179 MEDLINE on STN
TI Effects of **all-trans-retinoic acid** on the dermis of hairless mice.
- L18 ANSWER 60 OF 179 MEDLINE on STN
TI Corneal endothelial healing rate and the effect of topical **retinoic acid**.
- L18 ANSWER 61 OF 179 MEDLINE on STN
TI [Acne conglobata: unusual course in 13-cis-**retinoic acid** therapy].
Acne conglobata: Ungewöhnlicher Verlauf unter 13-cis-Retinsäuretherapie.
- L18 ANSWER 62 OF 179 MEDLINE on STN
TI The efficacy of **retinoic acid** ointment for treatment of xerophthalmia and corneal epithelial wounds.
- L18 ANSWER 63 OF 179 MEDLINE on STN
TI Vitamin A and **retinoic acid**: induced fibroblast differentiation in vitro.

MMP-13 inhibitors

- L18 ANSWER 64 OF 179 MEDLINE on STN
TI Corneal epithelial **wound healing** in normal and diabetic rabbits treated with **tretinoin**.
- L18 ANSWER 65 OF 179 MEDLINE on STN
TI Nonhealing erosions with granulation tissue in the treatment of acne lesions during isotretinoin therapy.
- L18 ANSWER 66 OF 179 MEDLINE on STN
TI Role of soluble myosin in cortical contractions of *Xenopus* eggs.
- L18 ANSWER 67 OF 179 MEDLINE on STN
TI The effects of retinoids on the replication of herpes simplex virus type 1.
- L18 ANSWER 68 OF 179 MEDLINE on STN
TI Healing of experimental corneal wounds treated with topically applied retinoids.
- L18 ANSWER 69 OF 179 MEDLINE on STN
TI Effect of dietary retinyl acetate, beta-carotene and **retinoic acid** on **wound healing** in rats.
- L18 ANSWER 70 OF 179 MEDLINE on STN
TI **Vitamin A acid** and corneal epithelial **wound healing**.
- L18 ANSWER 71 OF 179 MEDLINE on STN
TI [Effect of cyclic **guanosine** monophosphate on certain indices of muscle tissue carbohydrate metabolism during the wound process].
Vliianie tsiklicheskogo guanozinmonofosfata na nekotorye pokazateli uglevodnogo obmena myshechnoi tkani pri ranevom protsesse.
- L18 ANSWER 72 OF 179 MEDLINE on STN
TI Effect of cAMP and related compounds on newt epidermal cell migration both in vivo and in vitro.
- L18 ANSWER 73 OF 179 MEDLINE on STN
TI **Tretinoin** and corneal epithelial **wound healing**
- L18 ANSWER 74 OF 179 MEDLINE on STN
TI Mechanism of action of retinyl compounds on **wound healing** IV: effect of desmethylretinoic acid and its vinyllogs on granuloma formation.
- L18 ANSWER 75 OF 179 MEDLINE on STN
TI **Vitamin A acid** and **wound healing**.
- L18 ANSWER 76 OF 179 MEDLINE on STN
TI [Experimental studies on the relation between **wound healing** and local use of **vitamin A acid**].
Experimentelle Untersuchung uber Zusammenhange zwischen Wundheilung und lokaler Anwendung von Vitamin-A-Saure.
- L18 ANSWER 77 OF 179 MEDLINE on STN
TI Mechanism of action of retinyl compounds on **wound healing**. 3. Effect of **retinoic acid** homologs on granuloma formation.

MMP-13 inhibitors

L18 ANSWER 78 OF 179 MEDLINE on STN

TI Wound healing and vitamin A acid.

L18 ANSWER 79 OF 179 MEDLINE on STN

TI Accelerated rejection of skin homografts by vitamin A acid.

L18 ANSWER 80 OF 179 MEDLINE on STN

TI [The cicatrizing effects of purine nucleosides for topical use].
Sugli effetti cicatrizzanti di nucleosidi purinici per uso topico.

=> d L18 81-179 ti

L18 ANSWER 81 OF 179 MEDLINE on STN

TI [Action of **guanosine** and antacids on experimental gastric ulcer induced by reserpine].
Azione della guanosina e di antiacidi sull'ulcera gastrica sperimentale da reserpina.

L18 ANSWER 82 OF 179 MEDLINE on STN

TI Mechanism of action of salicylates. 8. Effect of topical application of **retinoic acid** on wound-healing retardation action of a few anti-inflammatory agents.

L18 ANSWER 83 OF 179 MEDLINE on STN

TI Studies on the mechanism of action of salicylates. VI. Effect of topical application of **retinoic acid** on wound-healing retardation action of salicylic acid.

L18 ANSWER 84 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN

TI Method for culturing and assaying cells of a specific patient for screening multiple therapeutic or chemotherapeutic agents

L18 ANSWER 85 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN

TI Uses for thyroid hormone compounds or thyroid hormone-like compounds

L18 ANSWER 86 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN

TI Multi-micro dilution technology for enhancing transdermal absorption

L18 ANSWER 87 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of retinoyloxy-(alkyl-substituted)-methyl butyrates useful for the treatment of cancer and other proliferative diseases

L18 ANSWER 88 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN

TI Cartilage-derived **retinoic acid**-sensitive protein and type II collagen expression during fracture healing are potential targets for Sox9 regulation

L18 ANSWER 89 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN

TI Screening methods and therapeutic formulations for cytokine inhibitors

L18 ANSWER 90 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN

TI Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage

L18 ANSWER 91 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN

TI Production and application of angiotropins

L18 ANSWER 92 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN

TI Identification of loci involved in accelerated wound healing and the development of new wound healing

MMP-13 inhibitors

promoters

- L18 ANSWER 93 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Therapeutic permeation enhanced-**wound healing** compositions containing antioxidant and lactate and fatty acids
- L18 ANSWER 94 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Defense and repair mechanisms in the airway epithelium exposed to oxidative stress. Effects of analogs of **retinoic acid**
- L18 ANSWER 95 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Topical preparations containing Artemisia extract
- L18 ANSWER 96 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Vitamin A-growth factor interactions in **wound healing**
- L18 ANSWER 97 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Comparison of the effects of **retinoic acid** on the regeneration of external and intracoelomic limbs of *Ambystoma mexicanum*
- L18 ANSWER 98 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Rho **guanosine** triphosphatase mediates the selective stabilization of microtubules induced by lysophosphatidic acid.
- L18 ANSWER 99 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmaceutical compositions containing inhibitors of **retinoic acid** activity for **wound healing**
- L18 ANSWER 100 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmaceutical compositions and methods using alcohols and analogs thereof for regulation of melanin content and treatment of skin and other diseases
- L18 ANSWER 101 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Arginine in burn injury improves cardiac performance and prevents bacterial translocation
- L18 ANSWER 102 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases
- L18 ANSWER 103 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Bioadhesive-**wound healing** compositions and methods for preparing and using same
- L18 ANSWER 104 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Acne treating-**wound healing** compositions and methods for preparing and using same
- L18 ANSWER 105 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of acyl peptides and their compositions for use as drugs
- L18 ANSWER 106 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Cytoprotective **wound healing** compositions containing cytotoxic agent, pyruvate, antioxidants, and fatty acids
- L18 ANSWER 107 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Defining a region of the human keratin 6a gene that confers inducible expression in stratified epithelia of transgenic mice
- L18 ANSWER 108 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Ionizable congeners of aromatic and aliphatic alcohols as antileukemia agents and cytoprotectants

MMP-13 inhibitors

- L18 ANSWER 109 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Novel uses for thyroid hormones or thyroid hormone-like compounds
- L18 ANSWER 110 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Acne treating-wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids
- L18 ANSWER 111 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of retinoid glycosides in topical pharmaceutical compositions
- L18 ANSWER 112 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Bioadhesive-wound healing composition
- L18 ANSWER 113 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Activation of a single **retinoic acid** receptor isoform mediates proximodistal respecification
- L18 ANSWER 114 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of ginsenoside Ro or a plant extract containing same for promotion of collagen synthesis for pharmaceuticals and cosmetics
- L18 ANSWER 115 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of naphthylalkenoates and -alkenylbenzoates as retinoate γ -receptor ligands
- L18 ANSWER 116 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Effect of **retinoic acid** on contraction of collagen gel induced by human gingival fibroblasts
- L18 ANSWER 117 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Role of nitric oxide in restitution of injured guinea pig gastric mucosa in vitro
- L18 ANSWER 118 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI **Retinoic acid**-induced cell death in the wound epidermis of regenerating zebrafish fins
- L18 ANSWER 119 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of zinc norfloxacin for treatment of burns and skin ulcer
- L18 ANSWER 120 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Effect of **retinoic acid** on contraction of collagen gel induced by fibroblasts
- L18 ANSWER 121 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Peptide compositions for use in pharmaceutical, cosmetic, and biotechnological applications
- L18 ANSWER 122 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Isoform-specific induction of a retinoid-responsive antigen after biolistic transfection of chimeric **retinoic acid** /thyroid hormone receptors into a regenerating limb
- L18 ANSWER 123 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Analysis of Hox-4.5 and Hox-3.6 expression during newt limb regeneration: Differential regulation of paralogous Hox genes suggest different roles for members of different Hox clusters
- L18 ANSWER 124 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Aqueous synthetic organ extracts
- L18 ANSWER 125 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Enhanced skin penetration system for improved topical delivery of drugs

MMP-13 inhibitors

- L18 ANSWER 126 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Enhanced skin penetration system for improved topical delivery of drugs
- L18 ANSWER 127 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Low-pH aqueous gels containing nonionic polyacrylamide derivatives
- L18 ANSWER 128 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Formulations of disinfectants containing hydrogen peroxide and **zinc acetate** for wounds
- L18 ANSWER 129 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of dibutyl adipate and isopropyl myristate in topical and transdermal drugs and cosmetics
- L18 ANSWER 130 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Cosmetic, pharmaceutical or food composition comprising a dispersion of lipid vesicles which contain a fatty acyl glucose
- L18 ANSWER 131 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Topical compositions containing retinoids as penetration enhancers
- L18 ANSWER 132 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Effect of tocoretinate on proliferation of normal human skin fibroblasts
- L18 ANSWER 133 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Effect of tocoretinate on migration of cells
- L18 ANSWER 134 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Stimulating effect of tocoretinate on granulation and angiogenesis
- L18 ANSWER 135 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Synergistic topical compositions containing live yeast cell derivative
- L18 ANSWER 136 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI A new type II keratin restricted to normal and regenerating limbs and tails is responsive to **retinoic acid**
- L18 ANSWER 137 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Topical compositions containing live yeast cell derivatives
- L18 ANSWER 138 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Retinoids enhance the number of EGF receptors in corneal endothelial cells
- L18 ANSWER 139 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Synergistic **wound-healing** compositions containing growth factors and retinoids
- L18 ANSWER 140 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Junctional communication is induced in migrating capillary endothelial cells
- L18 ANSWER 141 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Drugs for the treatment of skin disorders and tumors containing catecholic butanes and zinc compounds
- L18 ANSWER 142 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmacologically active compositions of catecholic butanes with zinc for treatment of skin diseases
- L18 ANSWER 143 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Cosmetic and pharmaceutical compositions containing retinoids or carotenoids in liposomes or lipidic lamella for treatment of skin

MMP-13 inhibitors

disorders

- L18 ANSWER 144 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Two-step procedure for decubitis ulcer healing and aqueous medium and topical ointment used in connection therewith
- L18 ANSWER 145 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Inhibition of conjunctival transdifferentiation by topical retinoids
- L18 ANSWER 146 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Macrophage factors affecting **wound healing**
- L18 ANSWER 147 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Studies on the recovery of wound burst strength in alloxan-treated rats
- L18 ANSWER 148 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Stabilization of aqueous creams containing a glycyrrhetic acid derivative by metal salts
- L18 ANSWER 149 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Vitamin A and corticosteroid interaction in **wound healing** in rats
- L18 ANSWER 150 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Treating psoriasis with vinyls of desmethyl **retinoic acid**
- L18 ANSWER 151 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI **Vitamin A acid** and **wound healing**
- L18 ANSWER 152 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Higher homolog of **retinoic acid**
- L18 ANSWER 153 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI **Retinoic acid** homolog for **wound healing**
- L18 ANSWER 154 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Zinc and **wound healing** in normal and chronically ill rats
- L18 ANSWER 155 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI **Wound healing**-promoting vinylene analogs of demethylretinoic acid
- L18 ANSWER 156 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI C22 homolog of **retinoic acid** and its salts for promoting **wound healing**
- L18 ANSWER 157 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Correction of retarded epidermal regeneration due to sulfamylon by administration of oral zinc
- L18 ANSWER 158 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Mechanism of action of retinyl compounds on **wound healing**. II. Effect of active retinyl derivatives on granuloma formation
- L18 ANSWER 159 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Mechanism of action of retinyl compounds on **wound healing**. I. Structural relation of retinyl compounds and **wound healing**

MMP-13 inhibitors

- L18 ANSWER 160 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Changes in sugar nucleotide and high-energy phosphate kinetics during in vivo development of sponge biopsy connective tissue
- L18 ANSWER 161 OF 179 CAPLUS COPYRIGHT 2006 ACS on STN
TI Effect of some products of tissue autolysis on the processes of degeneration
- L18 ANSWER 162 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Use of inhibitors of **retinoic acid** activity for **wound healing**.
- L18 ANSWER 163 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Study of pharmacodynamics of skin using in-vivo confocal scanning laser microscopy.
- L18 ANSWER 164 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Hyaluronic acid and skin: **Wound healing** and aging.
- L18 ANSWER 165 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Antagonistic effects of **retinoic acid** and calcium on heparin-binding EGF-like growth factor expression in human skin organ culture.
- L18 ANSWER 166 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Effect of **retinoic acid** of RPE cell proliferation, TGF-beta expression and **wound healing** of laser burns to RPE.
- L18 ANSWER 167 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI **Retinoic acid** restores transforming growth factor-beta-1 concentrations in a steroid-impaired **wound-healing** model.
- L18 ANSWER 168 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Choice of a carrier for suppositories containing 13-cis-**retinoic acid**.
- L18 ANSWER 169 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Laminin and basic FGF promote a differentiated phenotype in retinal pigmented epithelium.
- L18 ANSWER 170 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI EFFECTS OF GROWTH FACTORS AND CYTOKINES ON REGULATION OF EXPRESSION OF DIFFERENTIATION MARKERS IN HUMAN EPIDERMAL KERATINOCYTES.
- L18 ANSWER 171 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI EFFECT OF **RETINOIC ACID** AND CORTISONE ON **WOUND HEALING** CELL-MEDIATED IMMUNITY AND SURVIVAL IN BURNED MICE.
- L18 ANSWER 172 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

MMP-13 inhibitors

TI EPIDERMAL GROWTH FACTOR IN CATARACT WOUND HEALING.

L18 ANSWER 173 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI EFFECTS OF SYSTEMIC 13-CIS **RETINOIC ACID** ON DERMAL
WOUND HEALING IN-VIVO.

L18 ANSWER 174 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI TOPICAL **RETINOIC-ACID** ENHANCES THE REPAIR OF UV
DAMAGED DERMAL CONNECTIVE TISSUE.

L18 ANSWER 175 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI ENHANCED REPAIR OF UV INDUCED DERMAL DAMAGE BY TOPICAL **RETINOIC-
ACID**.

L18 ANSWER 176 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI TOPICAL VITAMIN A AND CORNEAL EPITHELIAL WOUND HEALING

L18 ANSWER 177 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI WOUND HEALING IN RATS FED SMALL SUPPLEMENTS OF RETINYL
ACETATE BETA CAROTENE OR **RETINOIC-ACID**.

L18 ANSWER 178 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI ACYCLO **GUANOSINE** AND CORNEAL WOUND HEALING.

L18 ANSWER 179 OF 179 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI VITAMIN A-**ACID** AND CORNEAL EPITHELIAL
WOUND HEALING.

=> s L18 and mamm?

L19 26 L18 AND MAMM?

=> d L19 1-26

L19 ANSWER 1 OF 26 MEDLINE on STN

AN 1998049322 MEDLINE

DN PubMed ID: 9389454

TI Expression of regeneration-associated cytoskeletal proteins reveals
differences and similarities between regenerating organs.

AU Ferretti P; Ghosh S

CS Developmental Biology Unit, Institute of Child Health, UCL, London,
England.. ferretti@ich.ucl.ac.uk

SO Developmental dynamics : an official publication of the American
Association of Anatomists, (1997 Nov) Vol. 210, No. 3, pp.
288-304.

Journal code: 9201927. ISSN: 1058-8388.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199802

ED Entered STN: 19980224

Last Updated on STN: 20000303

Entered Medline: 19980210

MMP-13 inhibitors

L19 ANSWER 2 OF 26 MEDLINE on STN
 AN 91104022 MEDLINE
 DN PubMed ID: 2271181
 TI EGF receptor activities in **mammalian** development.
 AU Adamson E D
 CS La Jolla Cancer Research Foundation, California.
 NC CA 28427 (NCI)
 HD21957 (NICHD)
 SO Molecular reproduction and development, (1990 Sep) Vol. 27, No. 1, pp. 16-22.
 Journal code: 8903333. ISSN: 1040-452X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199102
 ED Entered STN: 19910329
 Last Updated on STN: 20000303
 Entered Medline: 19910225

L19 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:888780 CAPLUS
 DN 143:206383
 TI Method for culturing and assaying cells of a specific patient for screening multiple therapeutic or chemotherapeutic agents
 IN Kornblith, Paul L.
 PA Precision Therapeutics, Inc., USA
 SO U.S., 11 pp., Cont.-in-part of U.S. Ser. No. 679,056.
 CODEN: USXXAM

DT Patent
 LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6933129	B1	20050823	US 1998-39957	19980316
	US 5728541	A	19980317	US 1996-679056	19960712 <--
	CA 2259984	AA	19980122	CA 1997-2259984	19970710 <--
	CN 1275885	A	20001206	CN 1997-196143	19970710
	US 6900027	B1	20050531	US 1998-40161	19980317
	US 2001051353	A1	20011213	US 1998-189310	19981110
	US 6416967	B2	20020709		
	US 2002192638	A1	20021219	US 2002-205887	20020726
	US 6887680	B2	20050503		
	US 2005202410	A1	20050915	US 2005-73931	20050308
	US 2005202411	A1	20050915	US 2005-81827	20050317
PRAI	US 1996-679056	A2	19960712		
	US 1998-39957	A2	19980316		
	US 1998-40161	A1	19980317		
	US 1998-95993	A2	19980611		
	US 2002-205887	A3	20020726		

RE.CNT 92 THERE ARE 92 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:561799 CAPLUS
 DN 131:167387
 TI Production and application of angiotropins
 IN Kieseewetter, Stefan; Seibt, Joerg-Volker; Noll, Michael
 PA Fraunhofer-Gesellschaft zur Foerderung der Angewandten Forschung e.V., Germany
 SO Ger., 34 pp.
 CODEN: GWXXAW
 DT Patent

MMP-13 inhibitors

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19810998	C1	19990826	DE 1998-19810998	19980313 <--
	CA 2323095	AA	19990923	CA 1999-2323095	19990209 <--
	WO 9947563	A2	19990923	WO 1999-EP834	19990209 <--
	WO 9947563	A3	19991111		
	W: CA, IL, IS, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1062239	A2	20001227	EP 1999-913150	19990209
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002506630	T2	20020305	JP 2000-536754	19990209
PRAI	DE 1998-19810998	A	19980313		
	WO 1999-EP834	W	19990209		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:136777 CAPLUS

DN 130:200931

TI Therapeutic permeation enhanced-wound healing
compositions containing antioxidant and lactate and fatty acids

IN Martin, Alain

PA Warner-Lambert Company, USA

SO U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 224,936, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5874479	A	19990223	US 1998-19457	19980205 <--
	JP 2002356421	A2	20021213	JP 2002-82387	19920115
	JP 2003231632	A2	20030819	JP 2002-362245	19920115
	ZA 9502911	A	19960828	ZA 1995-2911	19950407 <--
	US 5981606	A	19991109	US 1998-19316	19980205 <--
PRAI	US 1991-663500	B1	19910301		
	US 1993-53922	B2	19930426		
	US 1994-224936	B2	19940408		
	JP 1992-505329	A3	19920115		
	US 1997-37730P	P	19970202		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:197390 CAPLUS

DN 128:253008

TI Pharmaceutical compositions and methods using alcohols and analogs thereof
for regulation of melanin content and treatment of skin and other diseases

IN Brown, David A.; Khorlin, Alexander A.; Lesiak, Krystyna; Ren, Wu Yun

PA Codon Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9811882	A1	19980326	WO 1997-US16642	19970918 <--
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP,				

MMP-13 inhibitors

KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG,
 SI, SK, SL, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

CA 2266496 AA 19980326 CA 1997-2266496 19970918 <--
 AU 9745842 A1 19980414 AU 1997-45842 19970918 <--
 AU 740783 B2 20011115
 US 5990177 A 19991123 US 1997-933144 19970918 <--
 EP 957903 A1 19991124 EP 1997-944319 19970918 <--
 EP 957903 B1 20050810
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 US 6110975 A 20000829 US 1997-933145 19970918
 AT 301459 E 20050815 AT 1997-944319 19970918
 ES 2245465 T3 20060101 ES 1997-944319 19970918
 WO 9855085 A1 19981210 WO 1998-US5346 19980318 <--
 W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP,
 KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG,
 SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG

AU 9865659 A1 19981221 AU 1998-65659 19980318 <--
 US 6214888 B1 20010410 US 1998-86547 19980528
 US 6290937 B1 20010918 US 1998-85917 19980528
 US 2002141952 A1 20021003
 US 6623724 B2 20030923
 US 2004067209 A1 20040408 US 2003-667630 20030922
 US 6955804 B2 20051018
 PRAI US 1996-26577P P 19960918
 US 1997-35947P P 19970121
 US 1997-36863P P 19970204
 US 1997-48597P P 19970604
 US 1997-933143 B2 19970918
 WO 1997-US16642 W 19970918
 WO 1998-US5346 W 19980318
 US 1998-85917 A1 19980528
 OS MARPAT 128:253008
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:574520 CAPLUS
 DN 127:225309
 TI Bioadhesive-wound healing compositions and methods for
 preparing and using same
 IN Martin, Alain; Leung, Sau-hung S.
 PA Warner-Lambert Co., USA
 SO U.S., 131 pp., Cont.-in-part of U.S. Ser. No. 298,521, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5658956	A	19970819	US 1995-445824	19950522 <--
	JP 2002356421	A2	20021213	JP 2002-82387	19920115
	JP 2003231632	A2	20030819	JP 2002-362245	19920115
	CA 2194876	AA	19960307	CA 1995-2194876	19950707 <--
	WO 9606640	A1	19960307	WO 1995-US8568	19950707 <--

MMP-13 inhibitors

W: AU, CA, JP, MX, NZ, SG
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

AU 9530045	A1	19960322	AU 1995-30045	19950707 <--
AU 707353	B2	19990708		
EP 779820	A1	19970625	EP 1995-926209	19950707 <--
R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI				
JP 10505057	T2	19980519	JP 1996-508729	19950707 <--
NZ 290031	A	20010223	NZ 1995-290031	19950707
ZA 9507245	A	19970630	ZA 1995-7245	19950829 <--
US 5981606	A	19991109	US 1998-19316	19980205 <--
PRAI US 1991-663500	B1	19910301		
US 1993-53922	B2	19930426		
US 1994-298521	B2	19940830		
JP 1992-505329	A3	19920115		
US 1994-224936	B1	19940408		
US 1995-445824	A	19950522		
WO 1995-US8568	W	19950707		
US 1997-37730P	P	19970202		

L19 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:367739 CAPLUS

DN 125:19043

TI Bioadhesive-wound healing composition

IN Leung, Sau-Hung S.; Martin, Alain

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9606640	A1	19960307	WO 1995-US8568	19950707 <--
W: AU, CA, JP, MX, NZ, SG					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	US 5658956	A	19970819	US 1995-445824	19950522 <--
	AU 9530045	A1	19960322	AU 1995-30045	19950707 <--
	AU 707353	B2	19990708		
	EP 779820	A1	19970625	EP 1995-926209	19950707 <--
R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI					
	JP 10505057	T2	19980519	JP 1996-508729	19950707 <--
	ZA 9507245	A	19970630	ZA 1995-7245	19950829 <--
PRAI	US 1994-298521	A	19940830		
	US 1995-445824	A	19950522		
	US 1991-663500	B1	19910301		
	US 1993-53922	B2	19930426		
	WO 1995-US8568	W	19950707		

L19 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1993:525183 CAPLUS

DN 119:125183

TI Aqueous synthetic organ extracts

PA Schuelke und Mayr G.m.b.H., Germany

SO Ger. Offen., 23 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4139639	A1	19930603	DE 1991-4139639	19911202 <--
	WO 9310802	A1	19930610	WO 1992-DE1028	19921202 <--
W: JP, US					

MMP-13 inhibitors

	EP 552516	A1	19930728	EP 1992-250349	19921202 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	JP 06506000	T2	19940707	JP 1993-509719	19921202 <--
PRAI	DE 1991-4139639	A	19911202		
	DE 1992-4227633	A	19920818		
	WO 1992-DE1028	W	19921202		

L19 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:579847 CAPLUS
DN 115:179847
TI A new type II keratin restricted to normal and regenerating limbs and tails is responsive to **retinoic acid**
AU Ferretti, Patrizia; Brockes, Jeremy P.; Brown, Robin
CS Ludwig Inst. Cancer Res., UCL, London, W1P 8BT, UK
SO Development (Cambridge, United Kingdom) (1991), 111(2), 497-507
CODEN: DEVPED; ISSN: 0950-1991
DT Journal
LA English

L19 ANSWER 11 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 1999:189251 BIOSIS
DN PREV199900189251
TI Study of pharmacodynamics of skin using in-vivo confocal scanning laser microscopy.
AU Sadiq, I.; Kligman, D.; Pagnoni, A.; Costa, K.; Mills, O. H., Jr. [Reprint author]; Stoudemayer, T.; Kligman, A. M.
CS S.K.I.N., Inc., Conshohocken, PA, USA
SO Clinical Pharmacology and Therapeutics, (Feb., 1999) Vol. 65, No. 2, pp. 123. print.
Meeting Info.: One-hundredth Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. San Antonio, Texas, USA. March 18-20, 1999. American Society for Clinical Pharmacology and Therapeutics.
CODEN: CLPTAT. ISSN: 0009-9236.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 5 May 1999
Last Updated on STN: 5 May 1999

L19 ANSWER 12 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 1996:439247 BIOSIS
DN PREV199699152853
TI Hyaluronic acid and skin: **Wound healing** and aging.
AU Manuskiatti, Woraphong; Maibach, Howard I. [Reprint author]
CS Dep. Dermatol., UCSF, San Francisco, Box 0989, Surge 110, San Francisco, CA 94143-0989, USA
SO International Journal of Dermatology, (1996) Vol. 35, No. 8, pp. 539-547.
CODEN: IJDEBB. ISSN: 0011-9059.
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 26 Sep 1996
Last Updated on STN: 26 Sep 1996

L19 ANSWER 13 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 1996:248654 BIOSIS
DN PREV199698804783
TI Antagonistic effects of **retinoic acid** and calcium on

MMP-13 inhibitors

heparin-binding EGF-like growth factor expression in human skin organ culture.

AU Stoll, S. W. [Reprint author]; Xia, I. O. [Reprint author]; Elder, J. T.
CS Dep. Dermatol., Univ. Mich., Ann Arbor, MI, USA
SO Journal of Investigative Dermatology, (1996) Vol. 106, No. 4, pp. 910.
Meeting Info.: Annual Meeting of the Society for Investigative Dermatology. Washington, D.C., USA. May 1-5, 1996.
CODEN: JIDEAE. ISSN: 0022-202X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 31 May 1996
Last Updated on STN: 11 Jul 1996

L19 ANSWER 14 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 1995:200522 BIOSIS

DN PREV199598214822

TI Effect of **retinoic acid** of RPE cell proliferation, TGF-beta expression and **wound healing** of laser burns to RPE.

AU MacDonald, M. [Reprint author]; Fan, L.; Pannu, R.; Kovithavongs, K.; Peters, C. [Reprint author]; Tredget, E. E.; Ghahary, A.

CS Dep. Ophthalmol., Univ. Alberta, Edmonton, AB, Canada

SO Investigative Ophthalmology and Visual Science, (1995) Vol. 36, No. 4, pp. S98.

Meeting Info.: Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, Florida, USA. May 14-19, 1995.

CODEN: IOVSDA. ISSN: 0146-0404.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)

LA English

ED Entered STN: 5 May 1995

Last Updated on STN: 15 May 1995

L19 ANSWER 15 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 1995:21571 BIOSIS

DN PREV199598035871

TI **Retinoic acid** restores transforming growth factor-beta-1 concentrations in a steroid-impaired **wound-healing** model.

AU Ulland, Anders E. [Reprint author]; Gartner, Madeline H.; Richards, John R.; Caldwell, Michael D.

CS Dep. Surg., Univ. Minn. Med. Sch., Minneapolis, MN, USA

SO Surgical Forum, (1994) Vol. 45, No. 0, pp. 714-716.

CODEN: SUFOAX. ISSN: 0071-8041.

DT Article

LA English

ED Entered STN: 11 Jan 1995

Last Updated on STN: 12 Jan 1995

L19 ANSWER 16 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 1993:436992 BIOSIS

DN PREV199396091617

TI Choice of a carrier for suppositories containing 13-cis-**retinoic acid**.

AU Guzev, K. S. [Reprint author]; Gretsikii, V. M.; Kon', I. Ya.; Yakushkina, L. M.

CS Cent. Res. Dermatol.-Venerol. Inst., Moscow, Russia

MMP-13 inhibitors

SO Farmatsiya (Moscow), (1992) Vol. 41, No. 5, pp. 25-29.

CODEN: FRMTAL. ISSN: 0367-3014.

DT Article

LA Russian

ED Entered STN: 22 Sep 1993

Last Updated on STN: 23 Sep 1993

L19 ANSWER 17 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 1993:65226 BIOSIS

DN PREV199344030876

TI Laminin and basic FGF promote a differentiated phenotype in retinal pigmented epithelium.

AU Campochiaro, Peter; Hackett, Sean

CS Wilmer Inst., Baltimore, Md., USA

SO Experimental Eye Research, (1992) Vol. 55, No. SUPPL. 1, pp. S217.

Meeting Info.: X International Congress of Eye Research. Stresa, Italy. September 20, 1992.

CODEN: EXERA6. ISSN: 0014-4835.

DT Conference; (Meeting)

LA English

ED Entered STN: 15 Jan 1993

Last Updated on STN: 17 Mar 1993

L19 ANSWER 18 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 1991:267279 BIOSIS

DN PREV199140130159; BR40:130159

TI EFFECTS OF GROWTH FACTORS AND CYTOKINES ON REGULATION OF EXPRESSION OF DIFFERENTIATION MARKERS IN HUMAN EPIDERMAL KERATINOCYTES.

AU BLUMENBERG M [Reprint author]; JIANG C-K; CONNOLLY D; FREEDBERG I M

CS DEP DERMATOL, NY UNIV MED CENT, 550 FIRST AVE, NEW YORK, NY 10016, USA

SO Journal of Cellular Biochemistry Supplement, (1991) No. 15 PART F, pp. 166.

Meeting Info.: MEETING ON WOUND REPAIR HELD AT THE 20TH ANNUAL MEETING OF THE KEYSTONE SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY, KEYSTONE, COLORADO, USA, APRIL 1-7, 1991. J CELL BIOCHEM SUPPL.

ISSN: 0733-1959.

DT Conference; (Meeting)

FS BR

LA ENGLISH

ED Entered STN: 5 Jun 1991

Last Updated on STN: 6 Jun 1991

L19 ANSWER 19 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 1990:65320 BIOSIS

DN PREV199038031740; BR38:31740

TI EFFECT OF RETINOIC ACID AND CORTISONE ON WOUND HEALING CELL-MEDIATED IMMUNITY AND SURVIVAL IN BURNED MICE.

AU SOWDER L L [Reprint author]

CS DEP SURG, UNIV UTAH, SALT LAKE CITY, UTAH, USA

SO Surgical Forum (Chicago), (1989) Vol. 40, pp. 631-633.

Meeting Info.: 45TH ANNUAL SESSIONS OF THE FORUM ON FUNDAMENTAL SURGICAL PROBLEMS CLINICAL CONGRESS, ATLANTA, GEORGIA, USA, OCTOBER 15-20, 1989. SURG FORUM.

CODEN: SUFOAX. ISSN: 0071-8041.

DT Conference; (Meeting)

FS BR

LA ENGLISH

ED Entered STN: 16 Jan 1990

Last Updated on STN: 17 Jan 1990

MMP-13 inhibitors

L19 ANSWER 20 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 1989:327498 BIOSIS

DN PREV198937030270; BR37:30270

TI EPIDERMAL GROWTH FACTOR IN CATARACT WOUND HEALING.

AU FLAHERTY K T [Reprint author]; SCHULTZ G; EIFERMAN R A; ROBINSON M J;

ROBINSON C W; KIORPES T; GOODING R D

CS UNIV LOUISVILLE, LOUISVILLE, KY, USA

SO Investigative Ophthalmology and Visual Science, (1989) Vol. 30, No. 3 SUPPL, pp. 150.

Meeting Info.: ANNUAL SPRING MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, SARASOTA, FLORIDA, USA, APRIL 30-MAY 5, 1989. INVEST OPHTHALMOL VISUAL SCI.

CODEN: IOVSDA. ISSN: 0146-0404.

DT Conference; (Meeting)

FS BR

LA ENGLISH

ED Entered STN: 11 Jul 1989

Last Updated on STN: 14 Jul 1989

L19 ANSWER 21 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 1987:371790 BIOSIS

DN PREV198733062265; BR33:62265

TI EFFECTS OF SYSTEMIC 13-CIS RETINOIC ACID ON DERMAL WOUND HEALING IN-VIVO.

AU MOY R L [Reprint author]; ZITELLI J A; UITTO J

CS DEP OF DERMATOL, UNIV OF PITTSBURGH, PITTSBURGH, PA, USA

SO Clinical Research, (1987) Vol. 35, No. 3, pp. 705A.

Meeting Info.: MEETING OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY, SAN DIEGO, CALIFORNIA, USA, MAY 3-6, 1987. CLIN RES.

CODEN: CLREAS. ISSN: 0009-9279.

DT Conference; (Meeting)

FS BR

LA ENGLISH

ED Entered STN: 29 Aug 1987

Last Updated on STN: 29 Aug 1987

L19 ANSWER 22 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 1984:285402 BIOSIS

DN PREV198478021882; BA78:21882

TI TOPICAL RETINOIC-ACID ENHANCES THE REPAIR OF UV DAMAGED DERMAL CONNECTIVE TISSUE.

AU KLIGMAN L H [Reprint author]; DUO C H; KLIGMAN A M

CS DUHRING LAB, UNIV PA, PHILADELPHIA, PA, USA

SO Connective Tissue Research, (1984) Vol. 12, No. 2, pp. 139-150.

CODEN: CVTRBC. ISSN: 0300-8207.

DT Article

FS BA

LA ENGLISH

L19 ANSWER 23 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 1983:86674 BIOSIS

DN PREV198325011674; BR25:11674

TI ENHANCED REPAIR OF UV INDUCED DERMAL DAMAGE BY TOPICAL RETINOIC-ACID.

AU KLIGMAN L H [Reprint author]; CHEN H-D; KLIGMAN A M

CS DURHING LAB, UNIV PA SCH MED, PHILADELPHIA, PA, USA

SO Clinical Research, (1982) Vol. 30, No. 2, pp. 591A.

Meeting Info.: 43RD ANNUAL MEETING OF THE SOCIETY FOR INVESTIGATIVE

MMP-13 inhibitors

DERMATOLOGY, INC., WASHINGTON, D.C., USA, MAY 6-8, 1982. CLIN RES.
CODEN: CLREAS. ISSN: 0009-9279.

DT Conference; (Meeting)
FS BR
LA ENGLISH

L19 ANSWER 24 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

AN 1983:10865 BIOSIS

DN PREV198324010865; BR24:10865

TI TOPICAL VITAMIN A AND CORNEAL EPITHELIAL WOUND HEALING

AU UBELS J L [Reprint author]; EDELHAUSER H F; AUSTIN K H

CS MEDICAL COLLEGE OF WISCONSIN, MILWAUKEE, WIS, USA

SO Investigative Ophthalmology and Visual Science, (1982) Vol. 22,
No. 3 SUPPL, pp. 71.

Meeting Info.: ANNUAL SPRING MEETING OF THE ASSOCIATION FOR RESEARCH IN
VISION AND OPHTHALMOLOGY INCORPORATED, SARASOTA, FLA., USA, MAY 2-7, 1982.
INVEST OPHTHALMOL VISUAL SCI.

CODEN: IOVSDA. ISSN: 0146-0404.

DT Conference; (Meeting)
FS BR
LA ENGLISH

L19 ANSWER 25 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

AN 1981:104838 BIOSIS

DN PREV198121039834; BR21:39834

TI WOUND HEALING IN RATS FED SMALL SUPPLEMENTS OF RETINYL
ACETATE BETA CAROTENE OR RETINOIC-ACID.

AU GERBER L E [Reprint author]; ERDMAN J W JR

CS DEP FOOD SCI, UNIV ILLINOIS, URBANA, ILL 61801, USA

SO Federation Proceedings, (1981) Vol. 40, No. 3 PART 2, pp. 838.

Meeting Info.: 65TH ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES
FOR EXPERIMENTAL BIOLOGY, ATLANTA, GA., USA, APRIL 12-17, 1981. FED PROC.

CODEN: FEPA7. ISSN: 0014-9446.

DT Conference; (Meeting)
FS BR
LA ENGLISH

L19 ANSWER 26 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

AN 1981:34513 BIOSIS

DN PREV198120034513; BR20:34513

TI ACYCLO GUANOSINE AND CORNEAL WOUND HEALING.

AU LASS J H [Reprint author]; PAVAN-LANGSTON D; PARK N H

CS EYE RES INST RETINA FOUND, BOSTON, MASS, USA

SO Investigative Ophthalmology and Visual Science, (1979) No.
SUPPL, pp. 57.

Meeting Info.: ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION
AND OPHTHALMOLOGY INCORPORATED, SARASOTA, FLA., USA, APR. 30-MAY 4, 1979.
INVEST OPHTHALMOL VISUAL SCI.

CODEN: IOVSDA. ISSN: 0146-0404.

DT Conference; (Meeting)
FS BR
LA ENGLISH

=> l18 and (lens or retina or retinal)

L18 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

MMP-13 inhibitors

=> s l18 and (lens or retina or retinal)

L20 8 L18 AND (LENS OR RETINA OR RETINAL)

=> d L20 1-8 ti

L20 ANSWER 1 OF 8 MEDLINE on STN

TI Effect of **retinoic acid** on wound healing of laser burns to porcine **retinal** pigment epithelium.

L20 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of acyl peptides and their compositions for use as drugs

L20 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

TI Effect of **retinoic acid** on contraction of collagen gel induced by human gingival fibroblasts

L20 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

TI Topical compositions containing retinoids as penetration enhancers

L20 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

TI Synergistic **wound-healing** compositions containing growth factors and retinoids

L20 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

TI Higher homolog of **retinoic acid**

L20 ANSWER 7 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Effect of **retinoic acid** of RPE cell proliferation, TGF-beta expression and **wound healing** of laser burns to RPE.

L20 ANSWER 8 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Laminin and basic FGF promote a differentiated phenotype in **retinal** pigmented epithelium.

=> d L20 5 ti abs bib

L20 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

TI Synergistic **wound-healing** compositions containing growth factors and retinoids

AB Mixts. of peptide growth factors, having human mitogenic and angiogenic activity, and retinoids, are synergistic **wound-healing** promoters (no data). A cream comprised epidermal growth factor 0.01, **tretinoin** 0.05, xanthan gum 0.3, polyoxyl-40 stearate 5.0, stearyl alc. 3.0, stearic acid 19.0, iso-Pr myristate 10.0, butylated hydroxytoluene 0.1, citric acid 0.2, sorbic acid 0.05, and water to 100%.

AN 1990:484838 CAPLUS

DN 113:84838

TI Synergistic **wound-healing** compositions containing growth factors and retinoids

IN Sheffield, Warren D.; Mezick, James A.

PA Ethicon, Inc., USA

SO Eur. Pat. Appl., 6 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 339905	A2	19891102	EP 1989-304056	19890424 <--

MMP-13 inhibitors

EP 339905 A3 19910508
R: DE, FR, GB, IT
JP 01316327 A2 19891221 JP 1989-103590 19890425 <--
PRAI US 1988-185665 A 19880425

=> s regeneration or transdifferentiation or differentiation

L21 689223 REGENRATION OR TRANSDIFFERENTIATION OR DIFFERENTIATION

=> s L21 and retinoic

L22 21674 L21 AND RETINOIC

=> s L22 and mamma?

L23 7837 L22 AND MAMMA?

=> dup rem L23

PROCESSING IS APPROXIMATELY 39% COMPLETE FOR L23

PROCESSING IS APPROXIMATELY 62% COMPLETE FOR L23

PROCESSING IS APPROXIMATELY 84% COMPLETE FOR L23

PROCESSING COMPLETED FOR L23

L24 7183 DUP REM L23 (654 DUPLICATES REMOVED)

=> s L24 and py<2000

1 FILES SEARCHED...

L25 4827 L24 AND PY<2000

=> s L25 and guanosine

L26 9 L25 AND GUANOSINE

=> d L26 1-9 ti

L26 ANSWER 1 OF 9 MEDLINE on STN

TI Regulation of GTP biosynthesis.

L26 ANSWER 2 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Increased mRNA expression of phospholipase D (PLD) isozymes during granulocytic **differentiation** of HL60 cells.

L26 ANSWER 3 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Increased activity of small GTP-binding protein-dependent phospholipase D during **differentiation** in human promyelocytic leukemic HL60 cells.

L26 ANSWER 4 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Activation of Ras and formation of GAP complex during TPA-induced monocytic **differentiation** of HL-60 cells.

L26 ANSWER 5 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI **Retinoic** acid-induced **differentiation** of human neuroblastoma SH-SY5Y cells is associated with changes in the abundance of G proteins.

L26 ANSWER 6 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI RECIPROCAL ALTERATIONS OF GMP REDUCTASE AND IMP DEHYDROGENASE ACTIVITIES DURING **DIFFERENTIATION** IN HL-60 LEUKEMIA CELLS.

L26 ANSWER 7 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI SYNERGISTIC ACTION OF TIAZOFURIN AND **RETINOIC** ACID ON **DIFFERENTIATION** AND COLONY FORMATION OF HL-60 LEUKEMIA CELLS.

L26 ANSWER 8 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI MONOCYTOID **DIFFERENTIATION** OF FRESHLY ISOLATED HUMAN MYELOID LEUKEMIA CELLS AND HL-60 CELLS INDUCED BY THE GLUTAMINE ANTAGONIST

MMP-13 inhibitors

ACIVICIN.

L26 ANSWER 9 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI GRANULOCYTIC DIFFERENTIATION INDUCED BY RETINOIC-ACID
IN HL-60 CELLS IS ASSOCIATED WITH CHANGES IN ADENYLATE CYCLASE ACTIVITY.

=> s regeneration and mamma? and retinoic and guanosine

L27 0 REGENERATION AND MAMMA? AND RETINOIC AND GUANOSINE

=> s regeneration and retinoic and guanosine

L28 0 REGENERATION AND RETINOIC AND GUANOSINE

=> s regeneration and retinoic and guanosine

L29 2 REGENERATION AND RETINOIC AND GUANOSINE

=> d L29 1-2 ti

L29 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

TI Genes with differential expression profile between human dental pulp stem
cells and mesenchymal stem cells and use for regenerating tooth germ

L29 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

TI Methods for transdifferentiation of body tissues

=> d L29 1 ti abs bib

L29 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

TI Genes with differential expression profile between human dental pulp stem
cells and mesenchymal stem cells and use for regenerating tooth germ

AB The present invention relates to a group of genes whose expression profile
are different between human dental pulp stem cells and mesenchymal stem
cells, as well as a method for regenerating tooth germ using these genes.
According to the present invention, the gene expression profiles and
cluster anal. between human dental pulp stem cells (hDPSCs) and
mesenchymal stem cells (hMSCs) as representative populations of
odontoprogenitor and osteoprogenitor cell were revealed, and a group of
genes whose expression profile are different between human dental pulp
stem cells and mesenchymal stem cells was identified. By utilizing the
groups of the genes of the present invention together with the dental pulp
stem cells and mesenchymal stem cells, hard tissue such as tooth germ,
dental pulp, dentin or bone can be regenerated. The present inventors
investigated the gene expression profiles and cluster anal. between human
dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as
representative populations of odontoprogenitor and osteoprogenitor cells,
resp. At first, the present inventors confirmed the differential
expression of Alkaline phosphatase (ALP) activity, Dentin matrix protein 1
(DMP 1), Dentin phosphosialoprotein (DSPP) using by real time
reverse-transcriptase polymerase chain reaction (RT-PCR) in total RNA from
primary cultures. The number of genes in hDPSCs(I) that were up-regulated by
2>-fold, compared to hMSCs, was 614 (Table, IV). On the other hand, the
number of genes down regulated by <2-fold in hDPSCs (I) was 296 (Table III,
IV).

AN 2005:1020555 CAPLUS

DN 143:320266

TI Genes with differential expression profile between human dental pulp stem
cells and mesenchymal stem cells and use for regenerating tooth germ

IN Ueda, Minoru; Yamada, Yoichi

PA Hitachi Medical Corp., Japan

SO Jpn. Kokai Tokkyo Koho, 246 pp.

CODEN: JKXXAF

DT Patent

MMP-13 inhibitors

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2005253442	A2	20050922	JP 2004-111582	20040309
PRAI	JP 2004-111582		20040309		

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

932.46

988.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-4.50

-4.50

STN INTERNATIONAL LOGOFF AT 12:01:04 ON 21 APR 2006

MMP-13 inhibitors

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	8	JAN 30	Saved answer limit increased
NEWS	9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	14	FEB 28	TOXCENTER reloaded with enhancements
NEWS	15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	16	MAR 01	INSPEC reloaded and enhanced
NEWS	17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	18	MAR 08	X.25 communication option no longer available after June 2006
NEWS	19	MAR 22	EMBASE is now updated on a daily basis
NEWS	20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	22	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

MMP-13 inhibitors

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:54:27 ON 21 APR 2006

=> file medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 15:54:38 ON 21 APR 2006

FILE LAST UPDATED: 20 APR 2006 (20060420/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).

See also:

<http://www.nlm.nih.gov/mesh/>

http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html

http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (limb or organ) (w)regeneration

60627 LIMB

226989 ORGAN

63432 REGENERATION

L1 548 (LIMB OR ORGAN) (W)REGENERATION

=> s L1 nad py(2000

MISSING OPERATOR L1 NAD

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s L1 and py<2000

12400053 PY<2000

(PY<20000000)

L2 420 L1 AND PY<2000

=> sL2 and (mammal or mammalian)

SL2 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s L2 and (mammal or mammalian)

3377 MAMMAL

117785 MAMMALIAN

L3 17 L2 AND (MAMMAL OR MAMMALIAN)

MMP-13 inhibitors

=> d L3 1-17 ti

- L3 ANSWER 1 OF 17 MEDLINE on STN
TI A target of thrombin activation promotes cell cycle re-entry by urodele muscle cells.
- L3 ANSWER 2 OF 17 MEDLINE on STN
TI Design of an artificial skin. IV. Use of island graft to isolate **organ regeneration** from scar synthesis and other processes leading to skin wound closure.
- L3 ANSWER 3 OF 17 MEDLINE on STN
TI Regeneration versus neoplastic growth.
- L3 ANSWER 4 OF 17 MEDLINE on STN
TI Amphibian FGF-1 is structurally and functionally similar to but antigenically distinguishable from its **mammalian** counterpart.
- L3 ANSWER 5 OF 17 MEDLINE on STN
TI Amphibian **limb regeneration**: rebuilding a complex structure.
- L3 ANSWER 6 OF 17 MEDLINE on STN
TI Stabilizing role of the basement membrane and dermal fibers during newt **limb regeneration**.
- L3 ANSWER 7 OF 17 MEDLINE on STN
TI Applications of ECM analogs in surgery.
- L3 ANSWER 8 OF 17 MEDLINE on STN
TI Cloning and expression of the axolotl proto-oncogene ski.
- L3 ANSWER 9 OF 17 MEDLINE on STN
TI A newt type II keratin restricted to normal and regenerating limbs and tails is responsive to retinoic acid.
- L3 ANSWER 10 OF 17 MEDLINE on STN
TI Epidermis, basement membrane, and connective-tissue healing after amputation of mouse digits: implications for **mammalian** appendage regeneration.
- L3 ANSWER 11 OF 17 MEDLINE on STN
TI Structure and expression of a newt cardio-skeletal myosin gene. Implications for the C value paradox.
- L3 ANSWER 12 OF 17 MEDLINE on STN
TI Retinoic acid-binding protein in the axolotl: distribution in mature tissues and time of appearance during **limb regeneration**.
- L3 ANSWER 13 OF 17 MEDLINE on STN
TI Acetazolamide does not disrupt limb regenerate morphogenesis in the salamander, *Plethodon cinereus*.
- L3 ANSWER 14 OF 17 MEDLINE on STN
TI Requisites for growth and myelination of urodele sensory neurons in tissue culture.
- L3 ANSWER 15 OF 17 MEDLINE on STN
TI A comparison of beta-endorphin levels in regenerating and nonregenerating vertebrates.

MMP-13 inhibitors

L3 ANSWER 16 OF 17 MEDLINE on STN

TI Higher vertebrates do not regenerate digits and legs because the wound epidermis is not functional. A hypothesis.

L3 ANSWER 17 OF 17 MEDLINE on STN

TI Partial regeneration of the above-elbow amputated rat forelimb. I. Innate responses.

=> s L1 and (mammal or mammalian)

3377 MAMMAL

117785 MAMMALIAN

L4 35 L1 AND (MAMMAL OR MAMMALIAN)

=> d L3 2 5 10 16 27 ti abs bib

17 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE

The answer numbers requested are not in the answer set.

ENTER ANSWER NUMBER OR RANGE (1):2 5 10 16 17

L3 ANSWER 2 OF 17 MEDLINE on STN

TI Design of an artificial skin. IV. Use of island graft to isolate **organ regeneration** from scar synthesis and other processes leading to skin wound closure.

AB Deep skin wounds in the adult **mammal** close spontaneously by epithelialization, wound contraction, and scar synthesis. In previous wound healing studies, it has been unsuccessfully attempted to separate from each other the natural processes that close wounds. In this study, we attempted to isolate skin regeneration from spontaneous processes of wound closure using "island" grafts. A porous analog of the extracellular matrix, composed of a graft copolymer of type I collagen and chondroitin 6-sulfate, was seeded with uncultured autologous keratinocytes and served to induce regeneration of the dermis and the epidermis. Grafts of the copolymer, measuring 1 x 2 cm, were placed in the center of 5 x 6-cm wounds in guinea pigs. By day 14, the edges of the island grafts were clearly separated from the host epidermis and dermis by a distinct bed of granulation tissue. Histologic study of island grafts on day 14 showed that the copolymer grafts had largely degraded and that a new epidermis and dermis had been synthesized in its place. The thickness of the new epidermis increased as the density of cells seeded into the graft increased. No synthesis of epidermis or dermis was observed in the granulation tissue outside the perimeter of the island grafts. We conclude that island grafting allows the study of early events in skin regeneration in isolation from epithelialization, contraction, and scar synthesis.

AN 1998151175 MEDLINE

DN PubMed ID: 9492211

TI Design of an artificial skin. IV. Use of island graft to isolate **organ regeneration** from scar synthesis and other processes leading to skin wound closure.

AU Orgill D P; Yannas I V

CS Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

SO Journal of biomedical materials research, (1998 Mar 15) Vol. 39, No. 4, pp. 531-5.

Journal code: 0112726. ISSN: 0021-9304.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199804

ED Entered STN: 19980422

Last Updated on STN: 19980422

Entered Medline: 19980413

MMP-13 inhibitors

L3 ANSWER 5 OF 17 MEDLINE on STN

TI Amphibian limb regeneration: rebuilding a complex structure.

AB The ability to regenerate complex structures is widespread in metazoan phylogeny, but among vertebrates the urodele amphibians are exceptional. Adult urodeles can regenerate their limbs by local formation of a mesenchymal growth zone or blastema. The generation of blastemal cells depends not only on the local extracellular environment after amputation or wounding but also on the ability to reenter the cell cycle from the differentiated state. The blastema replaces structures appropriate to its proximodistal position. Axial identity is probably encoded as a graded property that controls cellular growth and movement through local cell interactions. The molecular basis is not understood, but proximodistal identity in newt blastemal cells may be respecified by signaling through a retinoic acid receptor isoform. The possibility of inducing a blastema on a **mammalian** limb cannot be discounted, although the molecular constraints are becoming clearer as we understand more about the mechanisms of urodele regeneration.

AN 97238912 MEDLINE

DN PubMed ID: 9082990

TI Amphibian limb regeneration: rebuilding a complex structure.

AU Brockes J P

CS Ludwig Institute for Cancer Research and Department of Biochemistry and Molecular Biology, University College London, 91 Riding House Street, London W1P 8BT, UK.. jerbroludwig.ucl.ac.uk

SO Science, (1997 Apr 4) Vol. 276, No. 5309, pp. 81-7. Ref: 55
Journal code: 0404511. ISSN: 0036-8075.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)

LA English

FS Priority Journals

EM 199704

ED Entered STN: 19970506

Last Updated on STN: 19970506

Entered Medline: 19970422

L3 ANSWER 10 OF 17 MEDLINE on STN

TI Epidermis, basement membrane, and connective-tissue healing after amputation of mouse digits: implications for **mammalian** appendage regeneration.

AB Soft tissues from amputation sites of mice were examined at both light and electron microscope levels to determine whether features of growth buds (blastemas), which are necessary for amphibian limb **regeneration**, exist in nonregenerating mice. Several such features were found. A small area of the wound bed was covered by wound epithelium which, as in regenerating newt limbs, initially lacked an underlying basement membrane. Serially sectioned digits revealed blastemalike growth in the subdermal layer surrounding periosteal chondrogenic cells. Mesenchymalike cells were seen among the fibroblasts and leucocytes within the proliferating tissues. However, no evidence of dedifferentiation was seen in the dermis, which persisted as an apparent intact obstruction to growth bud formation. Existence of the essential ingredients of growth buds and soft-tissue proliferation adjacent to chondrogenic cells proximally suggest that the tissues of **mammalian** healing may differ quantitatively rather than qualitatively from tissues of appendage regeneration. This premise is encouraging for efforts at growth enhancement in mammals.

AN 89226481 MEDLINE

DN PubMed ID: 2712355

TI Epidermis, basement membrane, and connective-tissue healing after

MMP-13 inhibitors

amputation of mouse digits: implications for **mammalian** appendage regeneration.

AU Neufeld D A
CS Department of Anatomy, University of South Dakota School of Medicine, Vermillion 57069.

SO The Anatomical record, (1989 Apr) Vol. 223, No. 4, pp. 425-32.
Journal code: 0370540. ISSN: 0003-276X.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198905

ED Entered STN: 19900306

Last Updated on STN: 19900306

Entered Medline: 19890531

L3 ANSWER 16 OF 17 MEDLINE on STN

TI Higher vertebrates do not regenerate digits and legs because the wound epidermis is not functional. A hypothesis.

AB The necessity of injury, nerves, and wound epidermis for urodele **limb regeneration** is well accepted. Whether one or more of these three factors is limiting in amputated nonregenerating limbs of other vertebrates is a problem area in need of resolution. One view, that higher vertebrates possess inadequate innervation for **limb regeneration** to occur, is not strongly supported by experimental results. Superinnervation of lizard and **mammalian** limbs fails to elicit **limb regeneration**. Furthermore, in the well-known cases of **mammalian** regeneration, deer antlers and rabbit ears, a nerve requirement has not been demonstrated. In urodeles, the wound epidermis has recently been shown to have the role of maintaining dedifferentiated cells of the amputated limb stump in the cell cycle. The result of this wound epidermal stimulus is a sufficient number of cell divisions such that blastema formation occurs. We postulate that in amputated limbs of higher vertebrates, the wound epidermis is nonfunctional. Dedifferentiated or undifferentiated cells are not maintained in the cell cycle and blastema formation therefore does not occur. Instead, tissue regeneration occurs precociously due to lack of a cycling stimulus. The scar tissue which forms at the limb tips of nonregenerating vertebrates is the result of a nonfunctional wound epidermis.

AN 83080222 MEDLINE

DN PubMed ID: 7173524

TI Higher vertebrates do not regenerate digits and legs because the wound epidermis is not functional. A hypothesis.

AU Tassava R A; Olsen C L

SO Differentiation; research in biological diversity, (1982) Vol. 22, No. 3, pp. 151-5.

Journal code: 0401650. ISSN: 0301-4681.

CY GERMANY, WEST: Germany, Federal Republic of

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198302

ED Entered STN: 19900317

Last Updated on STN: 19980206

Entered Medline: 19830225

L3 ANSWER 17 OF 17 MEDLINE on STN

TI Partial regeneration of the above-elbow amputated rat forelimb. I. Innate responses.

AB Although a number of recent studies describe the facilitation of **limb regeneration** by electrical and other forms of stimulation, little is known of innate regenerative capacity in the

MMP-13 inhibitors

mammalian limb. The present report describes spontaneous regenerative responses following subtotal forelimb amputation in the young white rat. In one group of animals the forelimb was amputated through the lower humerus and the skin sutured closed. In a second group, adjacent muscle tissue still attached to bone at its origin(s) was interposed between the cut surface of the humerus and the skin. Among animals of the first group (skin closure only) bone growth and limb regenerative responses were generally not observed. Animals of the second group displayed significant elaborations of cartilage and bone at the limb terminus. The appearance and subsequent modification of these tissues suggest that some capacity for **limb regeneration** exists innately in the young rat and can be more readily evoked than has been recognized heretofore. It is concluded that extant and forthcoming reports of electrically stimulated skeletal tissue growth, repair and regeneration among eutherial mammals should be examined to determine whether reported responses to stimulation represent advances beyond what might be expected from innate replacement processes alone.

AN 79154016 MEDLINE
DN PubMed ID: 430576
TI Partial regeneration of the above-elbow amputated rat forelimb. I. Innate responses.
AU Person P; Libbin R M; Shah D; Papierman S
SO Journal of morphology, (1979 Mar) Vol. 159, No. 3, pp. 427-38.
Journal code: 0406125. ISSN: 0362-2525.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197906
ED Entered STN: 19900315
Last Updated on STN: 19900315
Entered Medline: 19790611

=> d L4 1-35 ti

L4 ANSWER 1 OF 35 MEDLINE on STN
TI Salamander **limb regeneration** involves the activation of a multipotent skeletal muscle satellite cell population.

L4 ANSWER 2 OF 35 MEDLINE on STN
TI **Limb regeneration** in higher vertebrates: developing a roadmap.

L4 ANSWER 3 OF 35 MEDLINE on STN
TI Some principles of regeneration in **mammalian** systems.

L4 ANSWER 4 OF 35 MEDLINE on STN
TI Molecular mechanisms for thyroid hormone-induced remodeling in the amphibian digestive tract: a model for studying **organ regeneration**.

L4 ANSWER 5 OF 35 MEDLINE on STN
TI A single-cell analysis of myogenic dedifferentiation induced by small molecules.

L4 ANSWER 6 OF 35 MEDLINE on STN
TI Wound keratins in the regenerating epidermis of lizard suggest that the wound reaction is similar in the tail and limb.

L4 ANSWER 7 OF 35 MEDLINE on STN
TI **Mammalian** fetal **organ regeneration**.

MMP-13 inhibitors

- L4 ANSWER 8 OF 35 MEDLINE on STN
TI Regenerative capacity and the developing immune system.
- L4 ANSWER 9 OF 35 MEDLINE on STN
TI Facts and theories of induced **organ regeneration**.
- L4 ANSWER 10 OF 35 MEDLINE on STN
TI Digit regeneration is regulated by Msx1 and BMP4 in fetal mice.
- L4 ANSWER 11 OF 35 MEDLINE on STN
TI Canine hepatocyte growth factor: molecular cloning and characterization of the recombinant protein.
- L4 ANSWER 12 OF 35 MEDLINE on STN
TI Quantitative estimation of HRP-labeled sensory and motor neurons during nerve-dependent and nerve-independent periods of urodele **limb regeneration**.
- L4 ANSWER 13 OF 35 MEDLINE on STN
TI Regeneration or scarring: an immunologic perspective.
- L4 ANSWER 14 OF 35 MEDLINE on STN
TI Vertebrate **limb regeneration** and the origin of limb stem cells.
- L4 ANSWER 15 OF 35 MEDLINE on STN
TI Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants.
- L4 ANSWER 16 OF 35 MEDLINE on STN
TI A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration.
- L4 ANSWER 17 OF 35 MEDLINE on STN
TI Denervation retards but does not prevent toetip regeneration.
- L4 ANSWER 18 OF 35 MEDLINE on STN
TI Nerve dependency in scarless fetal wound healing.
- L4 ANSWER 19 OF 35 MEDLINE on STN
TI A target of thrombin activation promotes cell cycle re-entry by urodele muscle cells.
- L4 ANSWER 20 OF 35 MEDLINE on STN
TI Design of an artificial skin. IV. Use of island graft to isolate **organ regeneration** from scar synthesis and other processes leading to skin wound closure.
- L4 ANSWER 21 OF 35 MEDLINE on STN
TI Regeneration versus neoplastic growth.
- L4 ANSWER 22 OF 35 MEDLINE on STN
TI Amphibian FGF-1 is structurally and functionally similar to but antigenically distinguishable from its **mammalian** counterpart.
- L4 ANSWER 23 OF 35 MEDLINE on STN
TI Amphibian **limb regeneration**: rebuilding a complex structure.
- L4 ANSWER 24 OF 35 MEDLINE on STN
TI Stabilizing role of the basement membrane and dermal fibers during newt **limb regeneration**.

MMP-13 inhibitors

- L4 ANSWER 25 OF 35 MEDLINE on STN
TI Applications of ECM analogs in surgery.
- L4 ANSWER 26 OF 35 MEDLINE on STN
TI Cloning and expression of the axolotl proto-oncogene ski.
- L4 ANSWER 27 OF 35 MEDLINE on STN
TI A new type II keratin restricted to normal and regenerating limbs and tails is responsive to retinoic acid.
- L4 ANSWER 28 OF 35 MEDLINE on STN
TI Epidermis, basement membrane, and connective-tissue healing after amputation of mouse digits: implications for **mammalian** appendage regeneration.
- L4 ANSWER 29 OF 35 MEDLINE on STN
TI Structure and expression of a new cardio-skeletal myosin gene. Implications for the C value paradox.
- L4 ANSWER 30 OF 35 MEDLINE on STN
TI Retinoic acid-binding protein in the axolotl: distribution in mature tissues and time of appearance during **limb regeneration**.
- L4 ANSWER 31 OF 35 MEDLINE on STN
TI Acetazolamide does not disrupt limb regenerate morphogenesis in the salamander, *Plethodon cinereus*.
- L4 ANSWER 32 OF 35 MEDLINE on STN
TI Requisites for growth and myelination of urodele sensory neurons in tissue culture.
- L4 ANSWER 33 OF 35 MEDLINE on STN
TI A comparison of beta-endorphin levels in regenerating and nonregenerating vertebrates.
- L4 ANSWER 34 OF 35 MEDLINE on STN
TI Higher vertebrates do not regenerate digits and legs because the wound epidermis is not functional. A hypothesis.
- L4 ANSWER 35 OF 35 MEDLINE on STN
TI Partial regeneration of the above-elbow amputated rat forelimb. I. Innate responses.

=> d L4 7 ti abs bib

- L4 ANSWER 7 OF 35 MEDLINE on STN
TI **Mammalian fetal organ regeneration.**
AB The developing fetus has the remarkable ability to heal dermal skin wounds by regenerating normal epidermis and dermis with restoration of the extracellular matrix architecture, strength, and function. The biology responsible for scarless wound healing in skin is a paradigm for ideal tissue repair. This regenerative capacity is lost in late gestation when fetal wounds heal with fibrosis and scar. Early in gestation, fetal skin is developing at a rapid pace in a unique environment. Investigation of normal skin embryogenesis and comparison between early scarless and late scarring fetal wounds has revealed distinct differences in inflammatory response, cellular mediators, wound contraction, cytokines, growth factors, and extracellular matrix modulators. The knowledge gained from comparative observational studies has served as a base for experimental interventions in animal models to induce or ameliorate scar. Although much progress has been made over the past decade, the mechanism of fetal

MMP-13 inhibitors

wound healing remains largely unknown and attempts to mimic the scarless wound phenotype have not been completely successful. Identification of more key genes involved in skin regeneration may have implications in adult skin wounds and repair in other organ systems.

AN 2005159306 MEDLINE
DN PubMed ID: 15791945
TI **Mammalian fetal organ regeneration.**
AU Colwell Amy S; Longaker Michael T; Lorenz H Peter
CS Department of Surgery, Pediatric Surgical Research Laboratory, Stanford University School of Medicine, 257 Campus Drive, Stanford, CA 94305-5148, USA.
SO Advances in biochemical engineering/biotechnology, (2005) Vol. 93, pp. 83-100. Ref: 69
Journal code: 8307733. ISSN: 0724-6145.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200504
ED Entered STN: 20050329
Last Updated on STN: 20050422
Entered Medline: 20050421

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.22

5.43

STN INTERNATIONAL LOGOFF AT 16:00:52 ON 21 APR 2006